• Mohamed Nabil Elshafei, Ahmed El-Bardissy, Ahmed Khalil, Mohammed Danjuma, Mahmood Mubasher, Ibrahim Y Abubeker, and Mouhand F H Mohamed.
• Clinical Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
• Eur. J. Clin. Invest. 2021 Sep 1; 51 (9): e13645e13645.

BackgroundColchicine was recently repurposed for the management of coronavirus disease 2019 (COVID-19). This rapid review and meta-analysis aimed to assess colchicine's impact on mortality outcomes in COVID-19 patients.Materials And MethodsWe systematically searched PubMed, EMBASE, Google Scholar since their inception till 25/03/2021 for observational or controlled studies that reported mortality as an outcome. The mortality odd ratios were generated with their corresponding 95% confidence intervals utilizing the random-effects model.ResultsNine studies comprising 5522 patients met our inclusion criteria. Our meta-analysis revealed significantly lower mortality in the colchicine group (OR 0.35, 95% CI 0.25-0.48, I2 0%) compared with controls. A subgroup analysis limited to hospitalized patients (OR 0.35, 95% CI 0.25-0.50, I2 0%) revealed similarly lower mortality in the colchicine group.ConclusionsThis meta-analysis suggests a mortality benefit with colchicine when used in the treatment of COVID-19 patients. The majority of included studies were observational; thus, the findings of this review need to be further supported by the results of ongoing trials.© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

14 keywords...

hide…